Fisher Scientific acquires PSS World Medical
Fisher Scientific has acquired specialty medical marketer and distributor PSS World Medical in a tax-free, stock-for-stock transaction valued at $840 million. Fisher supplies laboratory supplies and equipment, e-commerce technology, and other services to
Fisher Scientific has acquired specialty medical marketer and distributor PSS World Medical in a tax-free, stock-for-stock transaction valued at $840 million. Fisher supplies laboratory supplies and equipment, e-commerce technology, and other services to the scientific research community.
In February, PSS hired an investment banking firm to help its board of directors investigate ways to increase the value of its stock for shareholders. PSS has been looking for an acquisition partner since then, the company said. The company had built a presence in the medical imaging industry through acquisitions and distribution agreements.
In 1996, PSS acquired Diagnostic Imaging. Three years later, Diagnostic Imaging signed an agreement with Philips Medical Systems North America that gave DI exclusive distribution rights to Philips Tomoscan EG CT and BV25 Gold Mobile C-arm systems. Last month Diagnostic Imaging revised a distribution agreement with SonoSite, allowing other companiessuch as ATL Ultrasoundto include the SonoSite 180 handheld ultrasound system with sales of their own ultrasound systems (SCAN 6/7/00).
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
